Su Y. Kim

742 total citations
11 papers, 391 citations indexed

About

Su Y. Kim is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Molecular Biology. According to data from OpenAlex, Su Y. Kim has authored 11 papers receiving a total of 391 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 3 papers in Genetics and 2 papers in Molecular Biology. Recurrent topics in Su Y. Kim's work include Chronic Lymphocytic Leukemia Research (3 papers), Advanced Breast Cancer Therapies (2 papers) and Cell death mechanisms and regulation (2 papers). Su Y. Kim is often cited by papers focused on Chronic Lymphocytic Leukemia Research (3 papers), Advanced Breast Cancer Therapies (2 papers) and Cell death mechanisms and regulation (2 papers). Su Y. Kim collaborates with scholars based in United States, Australia and United Kingdom. Su Y. Kim's co-authors include Zeng-Feng Wang, Robert L. Walker, Jonathan Keith Killian, Jerzy Lasota, Christopher Lau, Lee J. Helman, Paul S. Meltzer, Laura Jones, Markku Miettinen and Marbin Pineda and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Su Y. Kim

10 papers receiving 385 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Su Y. Kim United States	9	119	99	88	87	85	11	391
Peter Forsyth United Kingdom	7	104 0.9×	50 0.5×	103 1.2×	130 1.5×	67 0.8×	14	391
F Loong China	11	168 1.4×	41 0.4×	282 3.2×	63 0.7×	49 0.6×	19	612
Byung Woog Kang South Korea	10	66 0.6×	193 1.9×	241 2.7×	38 0.4×	107 1.3×	21	406
Mei Dong China	14	241 2.0×	79 0.8×	379 4.3×	46 0.5×	53 0.6×	49	775
Hilde Vranckx Belgium	6	89 0.7×	345 3.5×	47 0.5×	168 1.9×	395 4.6×	9	594
Jake Allred United States	8	55 0.5×	57 0.6×	258 2.9×	46 0.5×	15 0.2×	13	373
I‐Ting Yu Taiwan	12	91 0.8×	82 0.8×	113 1.3×	27 0.3×	12 0.1×	23	352
Markéta Kalinová Czechia	13	300 2.5×	71 0.7×	121 1.4×	232 2.7×	20 0.2×	38	581
R. Tubbs United States	9	99 0.8×	118 1.2×	115 1.3×	36 0.4×	8 0.1×	13	333
J.-O. Bay France	10	78 0.7×	82 0.8×	138 1.6×	122 1.4×	6 0.1×	24	370

Countries citing papers authored by Su Y. Kim

Since Specialization

Citations

This map shows the geographic impact of Su Y. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Su Y. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Su Y. Kim more than expected).

Fields of papers citing papers by Su Y. Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Su Y. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Su Y. Kim. The network helps show where Su Y. Kim may publish in the future.

Co-authorship network of co-authors of Su Y. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Su Y. Kim. A scholar is included among the top collaborators of Su Y. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Su Y. Kim. Su Y. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Davids, Matthew S., Andrew W. Roberts, Vaishalee P. Kenkre, et al.. (2021). Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clinical Cancer Research. 27(17). 4690–4695. 48 indexed citations

Handunnetti, Sasanka M., Mary Ann Anderson, Andrew W. Roberts, et al.. (2021). Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. SHILAP Revista de lepidopterología. 2(2). 266–271. 3 indexed citations

Mato, Anthony R., Jeff P. Sharman, Mei Wu, et al.. (2020). The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc</i> analyses from the phase III MURANO study. Haematologica. 107(1). 134–142. 11 indexed citations

Karol, Seth E., Thomas Alexander, Amit Budhraja, et al.. (2020). Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. The Lancet Oncology. 21(4). 551–560. 96 indexed citations

Shebley, Mohamad, Rajeev Menon, John P. Gibbs, et al.. (2018). Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse. The Journal of Clinical Pharmacology. 59(5). 625–637. 8 indexed citations

Shin, Hye Young, et al.. (2017). Factors Influencing Intravitreal Bevacizumab and Triamcinolone Treatment in Patients with Diabetic Macular Edema. European Journal of Ophthalmology. 27(6). 746–750. 18 indexed citations

Miettinen, Markku, Jonathan Keith Killian, Zeng-Feng Wang, et al.. (2013). Immunohistochemical Loss of Succinate Dehydrogenase Subunit A (SDHA) in Gastrointestinal Stromal Tumors (GISTs) Signals SDHA Germline Mutation. The American Journal of Surgical Pathology. 37(2). 234–240. 128 indexed citations

Sekulić, Aleksandar, Su Y. Kim, Galen Hostetter, et al.. (2010). Loss of Inositol Polyphosphate 5-Phosphatase Is an Early Event in Development of Cutaneous Squamous Cell Carcinoma. Cancer Prevention Research. 3(10). 1277–1283. 30 indexed citations

Kim, Su Y., Katherine A. Janeway, & Alberto S. Pappo. (2010). Pediatric and wild-type gastrointestinal stromal tumor: new therapeutic approaches. Current Opinion in Oncology. 22(4). 347–350. 11 indexed citations

10.

Shin, Min Sun, Su Y. Kim, Ja June Jang, et al.. (1999). In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas. The Journal of Pathology. 188(2). 207–212. 38 indexed citations

11.

Lee, Sug Hyung, Min Sun Shin, Su Y. Kim, et al.. (1999). In vivo expression of soluble Fas and FAP‐1: possible mechanisms of Fas resistance in human hepatoblastomas. The Journal of Pathology. 188(2). 207–212.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact